Neurovascular Embolization Market Forecasts to 2030 – Global Analysis By Product (Flow Diversion Devices, Aneurysm Clips, Embolic Coils, Liquid Embolic Agents/Systems and Other Products), Procedure (Arteriovenous Malformation (AVM) Embolization, Aneurysm

Neurovascular Embolization Market Forecasts to 2030 – Global Analysis By Product (Flow Diversion Devices, Aneurysm Clips, Embolic Coils, Liquid Embolic Agents/Systems and Other Products), Procedure (Arteriovenous Malformation (AVM) Embolization, Aneurysm Coiling and Embolization and Other Procedures), End User and By Geography

According to Stratistics MRC, the Global Neurovascular Embolization Market is accounted for $1.52 billion in 2023 and is expected to reach $2.67 billion by 2030 growing at a CAGR of 8.4% during the forecast period. Neurovascular embolization is a medical procedure used to treat various conditions affecting the blood vessels of the brain and nervous system. It involves the intentional introduction of embolic agents, such as particles, coils, or liquid substances, into the blood vessels to block or reduce blood flow to targeted areas employed to treat abnormal vascular structures. Furthermore, by occluding or reducing blood flow to the affected vessels, neurovascular embolization helps to alleviate symptoms, prevent further damage, and promote overall vascular stability.

According to the Brain Aneurysms Foundation, in the U.S., roughly 6.7 million people have unruptured brain aneurysms, leading to an annual rupture rate of 8-10 cases per 100,000.

Market Dynamics:

Driver:

Expansion of Healthcare Infrastructure

The expansion of healthcare infrastructure facilitates collaborative efforts between healthcare institutions, industry stakeholders, and regulatory bodies, fostering research and development initiatives. This expansion not only addresses the growing burden of neurovascular disorders but also enables timely diagnosis and intervention. Moreover, a collaborative environment supports the continuous improvement of embolic materials, delivery systems, and procedural techniques, contributing to the overall advancement of the neurovascular embolization field.

Restraint:

Limited awareness and education

The limited awareness can lead to underutilization of neurovascular embolization, with patients being directed towards alternative treatments. Lack of public education campaigns and information dissemination about the procedure can result in delayed diagnosis and treatment. Furthermore, the complexity of neurovascular embolization and the specialized skills required to perform the procedure can be a barrier to its widespread adoption, which is impeding this market expansion.

Opportunity:

Technological advancements

The advancements in technology and innovations in embolic materials, delivery systems, and imaging technologies have significantly improved the precision, safety, and efficacy of neurovascular embolization procedures. Advanced delivery systems, including microcatheters and navigation tools, enable neurointerventionalists to reach intricate vascular structures. Furthermore, the integration of artificial intelligence (AI) and machine learning further refines procedural planning and execution, optimizing outcomes and reducing procedural times, which drive this market growth.

Threat:

Economic downturns

Economic downturns impact patients' ability to afford neurovascular embolization procedures and often face constraints and cost-cutting measures. This can lead to a reduction in funding for medical procedures, and individuals may face challenges in securing adequate health insurance coverage or may have limited resources. Additionally, economic downturns can disrupt the overall healthcare ecosystem, including physician practices and referral patterns. Physicians may experience reduced patient volumes or changes, which are hampering this market.

Covid-19 Impact

The COVID-19 pandemic has had several negative impacts on the neurovascular embolization market. The pandemic led to disruptions in healthcare services globally, procedures including certain neurovascular interventions like embolization, which were deferred or cancelled, impacting the overall procedural volume. Logistic challenges also impacted the availability of medical devices, including those used in neurovascular embolization. In addition, the shift in healthcare priorities and the financial strain on healthcare systems also hindered this market size.

The embolic coils segment is expected to be the largest during the forecast period

The embolic coil segment is estimated to hold the largest share due to its focus on the treatment of vascular abnormalities in the brain. This technique involves the deployment of platinum or other biocompatible coils through a catheter directly into the blood vessel. These coils induce clot formation, promoting the natural healing process and preventing the risk of rupture. In addition, it is versatile in treating cerebrovascular conditions, including aneurysms and arteriovenous malformations, coupled with ongoing research and development efforts that are boosting this segment’s expansion.

The aneurysm coiling and embolization segment is expected to have the highest CAGR during the forecast period

The aneurysm coiling and embolization segment is anticipated to have highest CAGR during the forecast period. It is a crucial intervention for treating vascular abnormalities in the brain, wherein a catheter is navigated through blood vessels to the site of the aneurysm. Platinum coils or other embolic devices are then deployed into the aneurysm, promoting blood clot formation and preventing rupture. Furthermore, aneurysm coiling and embolization procedures offer reduced invasiveness, shorter recovery times, and a lower risk of complications, and rising awareness among both healthcare providers and patients contributes to the sustained growth of this market.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period, owing to increased demand and advancements in healthcare infrastructure. Increasing healthcare awareness, improved diagnostic capabilities, and expanding access to healthcare services have heightened the demand for neurovascular embolization procedures. Furthermore, collaborative efforts between healthcare institutions and industry players have resulted in the development and introduction of innovative embolic materials and devices, which are driving this region’s growth.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period, owing to a growing awareness of advanced neurointerventional procedures, including embolization. Key players such as Medtronic plc, Penumbra, Inc., MicroVention, and Acandis GmbH continue to evolve technological advancements in healthcare systems, contributing to improved patient outcomes. Furthermore, increasing incidences of cerebrovascular diseases, such as aneurysms and arteriovenous, are propelling this region’s expansion.

Key players in the market

Some of the key players in the Neurovascular Embolization Market include Cerenovus, Penumbra Inc, Medtronic, Phenox GmbH, Stryker, Balt SAS, Shape Memory Medical Inc, Integra LifeSciences, B. Braun Melsungen AG, MicroVention Inc, Peter Lazic GmbH and Spartan Micro.

Key Developments:

In August 2023, Medtronic announced the outcome of the U.S. Food & Drug Administration (FDA) Circulatory System Devices Panel (CSDP) meeting to review data presented in support of the Medtronic Symplicity Spyral™ Renal Denervation (RDN) System.

In February 2022, CERENOVUS, an emerging leader in neurovascular care and part of Johnson & Johnson Medical Devices Companies,* announced the launch of EMBOGUARD™, a next generation balloon guide catheter to be used in endovascular procedures, including those for patients with acute ischemic stroke.

In June 2021, Johnson & Johnson Medical Devices Companies* announced the first patient was enrolled in the CERENOVUS-sponsored MEMBRANE study evaluating TruFill® n-BCA Liquid Embolic System in the embolization of middle meningeal artery (MMA) for treatment of chronic subdural hematoma (cSDH) as adjunct to surgical evacuation or as a stand-alone treatment.

In January 2020, MicroVention, Inc., a U.S. based subsidiary of Terumo and a global neurovascular company announced the FDA Premarket Approval (PMA) for the FRED® (Flow Re-Direction Endoluminal Device) device for the treatment of brain aneurysms.

Products Covered:
• Flow Diversion Devices
• Aneurysm Clips
• Embolic Coils
• Liquid Embolic Agents/Systems
• Other Products

Procedures Covered:
• Arteriovenous Malformation (AVM) Embolization
• Aneurysm Coiling and Embolization
• Other Procedures

End Users Covered:
• Specialty Clinics
• Hospitals
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
JapanChinaIndiaAustralia
New Zealand
South Korea
Rest of Asia Pacific• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances